PRA Health Sciences, Phase 2/3 Outpatient and CNS Clinic — Salt Lake City, Utah

PRA Health Sciences, Phase 2/3 Outpatient and CNS Clinic is a clinical research site located in Salt Lake City, Utah, United States 84106.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

PRA Health Sciences, Phase 2/3 Outpatient and CNS Clinic has participated in 1 clinical trials.

Therapeutic areas: Behavioral Variant Frontotemporal Dementia (bvFTD).

Sponsors: TauRx Therapeutics Ltd.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Salt Lake City

Browse all research sites in Utah · View every site in Salt Lake City

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for PRA Health Sciences, Phase 2/3 Outpatient and CNS Clinic?

PRA Health Sciences, Phase 2/3 Outpatient and CNS Clinic has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has PRA Health Sciences, Phase 2/3 Outpatient and CNS Clinic conducted?

PRA Health Sciences, Phase 2/3 Outpatient and CNS Clinic has 1 clinical trials on record. Their work covers Behavioral Variant Frontotemporal Dementia (bvFTD).

Is PRA Health Sciences, Phase 2/3 Outpatient and CNS Clinic accredited by Crixeo Clinical Trials?

PRA Health Sciences, Phase 2/3 Outpatient and CNS Clinic has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about PRA Health Sciences, Phase 2/3 Outpatient and CNS Clinic?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.